These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24019330)

  • 21. Characterization of a new class of androgen receptor antagonists with potential therapeutic application in advanced prostate cancer.
    Li H; Hassona MD; Lack NA; Axerio-Cilies P; Leblanc E; Tavassoli P; Kanaan N; Frewin K; Singh K; Adomat H; Böhm KJ; Prinz H; Guns ET; Rennie PS; Cherkasov A
    Mol Cancer Ther; 2013 Nov; 12(11):2425-35. PubMed ID: 23939374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells.
    Gaur S; Gross ME; Liao CP; Qian B; Shih JC
    Prostate; 2019 May; 79(6):667-677. PubMed ID: 30693539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The evolving role of enzalutamide on the treatment of prostate cancer.
    Nadal R; Bellmunt J
    Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Down-Regulation of the Androgen Receptor by G-Quadruplex Ligands Sensitizes Castration-Resistant Prostate Cancer Cells to Enzalutamide.
    Tassinari M; Cimino-Reale G; Nadai M; Doria F; Butovskaya E; Recagni M; Freccero M; Zaffaroni N; Richter SN; Folini M
    J Med Chem; 2018 Oct; 61(19):8625-8638. PubMed ID: 30188709
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
    Zhu Y; Dalrymple SL; Coleman I; Zheng SL; Xu J; Hooper JE; Antonarakis ES; De Marzo AM; Meeker AK; Nelson PS; Isaacs WB; Denmeade SR; Luo J; Brennen WN; Isaacs JT
    Oncogene; 2020 Nov; 39(45):6935-6949. PubMed ID: 32989253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it.
    Wang Y; Chen J; Wu Z; Ding W; Gao S; Gao Y; Xu C
    Br J Pharmacol; 2021 Jan; 178(2):239-261. PubMed ID: 33150960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug Resistance of Enzalutamide in CRPC.
    Chen X; Lu J; Xia L; Li G
    Curr Drug Targets; 2018; 19(6):613-620. PubMed ID: 28413979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enzalutamide (Xtandi) for patients with metastatic, resistant prostate cancer.
    Bennett LL; Ingason A
    Ann Pharmacother; 2014 Apr; 48(4):530-7. PubMed ID: 24458946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.
    Kranzbühler B; Salemi S; Mortezavi A; Sulser T; Eberli D
    Prostate; 2019 Feb; 79(2):206-214. PubMed ID: 30345525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of telomerase potentiates enzalutamide efficiency of androgen-sensitive human prostate cancer cells.
    Gecgel KK; Muduroglu M; Erdogan S
    J BUON; 2017; 22(6):1570-1576. PubMed ID: 29332354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enzalutamide: looking back at its preclinical discovery.
    Ha YS; Kim IY
    Expert Opin Drug Discov; 2014 Jul; 9(7):837-45. PubMed ID: 24820058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide.
    Modena A; Ciccarese C; Fantinel E; Bimbatti D; Tortora G; Massari F
    Expert Rev Anticancer Ther; 2015; 15(9):1037-48. PubMed ID: 26134919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative assessment of prognostic outcomes between first-generation antiandrogens and novel androgen-receptor-axis-targeted agents in patients with non-metastatic castration-resistant prostate cancer.
    Miyake H; Matsushita Y; Watanabe H; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
    Int J Clin Oncol; 2019 Jul; 24(7):842-847. PubMed ID: 30739263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enzalutamide: a novel anti-androgen with prolonged survival rate in CRPC patients.
    Dhingra R; Sharma T; Singh S; Sharma S; Tomar P; Malhotra M; Bhardwaj TR
    Mini Rev Med Chem; 2013 Aug; 13(10):1475-86. PubMed ID: 23701654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer.
    Semenas J; Dizeyi N; Persson JL
    Drug Des Devel Ther; 2013; 7():875-81. PubMed ID: 24009414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer: AR aberrations and resistance to abiraterone or enzalutamide.
    Attard G; Antonarakis ES
    Nat Rev Urol; 2016 Dec; 13(12):697-698. PubMed ID: 27804988
    [No Abstract]   [Full Text] [Related]  

  • 38. Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor.
    Quintela ML; Mateos LL; Estévez SV; Calvo OF; Herranz UA; Afonso FJ; Santomé L; Aparicio LA
    Cancer Treat Rev; 2015 Mar; 41(3):247-53. PubMed ID: 25638257
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.
    Rathkopf DE; Smith MR; Ryan CJ; Berry WR; Shore ND; Liu G; Higano CS; Alumkal JJ; Hauke R; Tutrone RF; Saleh M; Chow Maneval E; Thomas S; Ricci DS; Yu MK; de Boer CJ; Trinh A; Kheoh T; Bandekar R; Scher HI; Antonarakis ES
    Ann Oncol; 2017 Sep; 28(9):2264-2271. PubMed ID: 28633425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer.
    Loriot Y; Eymard JC; Patrikidou A; Ileana E; Massard C; Albiges L; Di Palma M; Escudier B; Fizazi K
    Eur J Cancer; 2015 Sep; 51(14):1946-52. PubMed ID: 26208462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.